CSL LIMITED - Announcements

0.21%

$263.27

Market Cap $127.4B

Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus... CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others. More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) to benefit as Denmark commits to cannabis pilot program.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

CSL	FY2015 Results Announcement and Analysts Presentation	PRICE SENSITIVE	12/08/15	1.74MB	Share
CSL	Appendix 4E Directors Report and Financial Statements	PRICE SENSITIVE	12/08/15	690.79KB	Share
CSL	Update on Novartis Influenza Vaccine Acquisition	PRICE SENSITIVE	31/07/15	61.87KB	Share
CSL	US FDA Accepts for Review rFVIII BLA	PRICE SENSITIVE	28/07/15	42.39KB	Share
CSL	CSL Behring to Present Pivotal Data	PRICE SENSITIVE	17/06/15	92.89KB	Share
CSL	Appendix 4D, Half Year Results Release and Briefing	PRICE SENSITIVE	11/02/15	2.05MB	Share
CSL	Placement	PRICE SENSITIVE	13/11/14	59.02KB	Share
CSL	Changes relating to buy-back - Appendix 3D	PRICE SENSITIVE	31/10/14	77.12KB	Share
CSL	CSL to acquire Novartis influenza vaccine business	PRICE SENSITIVE	27/10/14	442.42KB	Share
CSL	Announcement of buy-back - Appendix 3C	PRICE SENSITIVE	15/10/14	516.62KB	Share
CSL	Chairman's Address to Shareholders	PRICE SENSITIVE	15/10/14	5.72MB	Share
CSL	Appendix 4E, FY Results and Analysts Presentation	PRICE SENSITIVE	13/08/14	1.39MB	Share
CSL	Changes relating to buy-back - Appendix 3D	PRICE SENSITIVE	26/03/14	229.33KB	Share
CSL	Half Yearly Report and Accounts	PRICE SENSITIVE	12/02/14	1.32MB	Share
CSL	Changes relating to buy-back - Appendix 3D	PRICE SENSITIVE	01/11/13	94.69KB	Share
CSL	Announcement of buy-back - Appendix 3C	PRICE SENSITIVE	16/10/13	77.41KB	Share
CSL	Chairman's Address to Shareholders	PRICE SENSITIVE	16/10/13	1.38MB	Share
CSL	CSL Settles US Class Action and Updated Profit Guidance	PRICE SENSITIVE	07/10/13	59.39KB	Share
CSL	Full Year Results, Appendix 4E and Analysts Presentation	PRICE SENSITIVE	14/08/13	2.25MB	Share
CSL	Changes relating to buy-back - Appendix 3D	PRICE SENSITIVE	11/06/13	95.05KB	Share
CSL	New US$500 million Private Placement	PRICE SENSITIVE	28/03/13	40.11KB	Share
CSL	Appointment of Paul Perreault as Executive Director	PRICE SENSITIVE	13/02/13	32.08KB	Share
CSL	Half Yearly Report and Accounts	PRICE SENSITIVE	13/02/13	1.42MB	Share
CSL	CSL Lifts Profit Guidance	PRICE SENSITIVE	27/11/12	50.64KB	Share
CSL	Changes relating to buy-back - Appendix 3D	PRICE SENSITIVE	01/11/12	73.75KB	Share
CSL	Announcement of buy-back - Appendix 3C	PRICE SENSITIVE	17/10/12	89.61KB	Share
CSL	Full Year Results, Appendix 4E and Analysts Presentation	PRICE SENSITIVE	22/08/12	3.9MB	Share
CSL	CEO Succession	PRICE SENSITIVE	03/08/12	36.47KB	Share
CSL	Changes relating to buy-back - Appendix 3D	PRICE SENSITIVE	19/03/12	66.27KB	Share
CSL	Half Year Report and Accounts	PRICE SENSITIVE	22/02/12	950.46KB	Share
CSL	Changes relating to buy-back - Appendix 3D	PRICE SENSITIVE	09/11/11	85.5KB	Share
CSL	Announcement of buy-back	PRICE SENSITIVE	19/10/11	21.63KB	Share
CSL	Chairmans and MDs address to shareholders	PRICE SENSITIVE	19/10/11	268.59KB	Share
CSL	Full Year Results, Appendix 4E and Analysts Presentation	PRICE SENSITIVE	17/08/11	1.08MB	Share
CSL	Recombinant Technologies	PRICE SENSITIVE	20/05/11	64.4KB	Share
CSL	Half Yearly Report and Accounts	PRICE SENSITIVE	16/02/11	913.55KB	Share
CSL	Chairman's Address to Shareholders	PRICE SENSITIVE	13/10/10	268.63KB	Share
CSL	Announcement of buy-back - Appendix 3C	PRICE SENSITIVE	18/08/10	70.86KB	Share
CSL	Full Year Results, Appendix 4E and Analysts Presentation	PRICE SENSITIVE	18/08/10	1.74MB	Share
CSL +PAB	Patrys Reaches First Milestone in CSL Collaboration	PRICE SENSITIVE	28/05/10	192.44KB	Share
CSL	Response to an ASX Query	PRICE SENSITIVE	23/04/10	217.52KB	Share
CSL	Half Yearly Report and Accounts	PRICE SENSITIVE	17/02/10	323.48KB	Share
CSL +PAB	Patrys - CSL Collaboration	PRICE SENSITIVE	28/01/10	79.32KB	Share
CSL	Changes relating to buy-back - Appendix 3D	PRICE SENSITIVE	20/10/09	14.98KB	Share
CSL	Chairman's and MD's Address to Shareholders	PRICE SENSITIVE	14/10/09	350.44KB	Share
CSL	Full Year Results, Appendix 4E and Analysts Presentation	PRICE SENSITIVE	19/08/09	1.8MB	Share
CSL	Accounting Treatment - Conversion of US $1.5B to AUD	PRICE SENSITIVE	22/06/09	82.73KB	Share
CSL	Phosphagenics signs agreement with CSL	PRICE SENSITIVE	19/06/09	18.63KB	Share
CSL	CSL and Talecris agree to terminate Merger Agreement	PRICE SENSITIVE	09/06/09	104.67KB	Share
CSL	CSL announces on-market share buyback	PRICE SENSITIVE	09/06/09	82.45KB	Share
CSL	Announcement of buy-back - Appendix 3C	PRICE SENSITIVE	09/06/09	17.46KB	Share
CSL	CSL Receives Order from U.S,. Government for H1N1 Vaccine	PRICE SENSITIVE	29/05/09	35.51KB	Share
CSL	Confirms commitment to Talecris acquisition	PRICE SENSITIVE	28/05/09	89.17KB	Share
CSL	Proposed Acquisition of Talecris	PRICE SENSITIVE	07/05/09	33.74KB	Share
CSL	Half Yearly Report and Accounts	PRICE SENSITIVE	18/02/09	1.13MB	Share

CSL FY2015 Results Announcement and Analysts Presentation
12/08/15	PRICE SENSITIVE	1.74MB	Share
CSL Appendix 4E Directors Report and Financial Statements
12/08/15	PRICE SENSITIVE	690.79KB	Share
CSL Update on Novartis Influenza Vaccine Acquisition
31/07/15	PRICE SENSITIVE	61.87KB	Share
CSL US FDA Accepts for Review rFVIII BLA
28/07/15	PRICE SENSITIVE	42.39KB	Share
CSL CSL Behring to Present Pivotal Data
17/06/15	PRICE SENSITIVE	92.89KB	Share
CSL Appendix 4D, Half Year Results Release and Briefing
11/02/15	PRICE SENSITIVE	2.05MB	Share
CSL Placement
13/11/14	PRICE SENSITIVE	59.02KB	Share
CSL Changes relating to buy-back - Appendix 3D
31/10/14	PRICE SENSITIVE	77.12KB	Share
CSL CSL to acquire Novartis influenza vaccine business
27/10/14	PRICE SENSITIVE	442.42KB	Share
CSL Announcement of buy-back - Appendix 3C
15/10/14	PRICE SENSITIVE	516.62KB	Share
CSL Chairman's Address to Shareholders
15/10/14	PRICE SENSITIVE	5.72MB	Share
CSL Appendix 4E, FY Results and Analysts Presentation
13/08/14	PRICE SENSITIVE	1.39MB	Share
CSLChanges relating to buy-back - Appendix 3D
26/03/14	PRICE SENSITIVE	229.33KB	Share
CSLHalf Yearly Report and Accounts
12/02/14	PRICE SENSITIVE	1.32MB	Share
CSLChanges relating to buy-back - Appendix 3D
01/11/13	PRICE SENSITIVE	94.69KB	Share
CSLAnnouncement of buy-back - Appendix 3C
16/10/13	PRICE SENSITIVE	77.41KB	Share
CSLChairman's Address to Shareholders
16/10/13	PRICE SENSITIVE	1.38MB	Share
CSLCSL Settles US Class Action and Updated Profit Guidance
07/10/13	PRICE SENSITIVE	59.39KB	Share
CSLFull Year Results, Appendix 4E and Analysts Presentation
14/08/13	PRICE SENSITIVE	2.25MB	Share
CSLChanges relating to buy-back - Appendix 3D
11/06/13	PRICE SENSITIVE	95.05KB	Share
CSLNew US$500 million Private Placement
28/03/13	PRICE SENSITIVE	40.11KB	Share
CSLAppointment of Paul Perreault as Executive Director
13/02/13	PRICE SENSITIVE	32.08KB	Share
CSLHalf Yearly Report and Accounts
13/02/13	PRICE SENSITIVE	1.42MB	Share
CSLCSL Lifts Profit Guidance
27/11/12	PRICE SENSITIVE	50.64KB	Share
CSLChanges relating to buy-back - Appendix 3D
01/11/12	PRICE SENSITIVE	73.75KB	Share
CSLAnnouncement of buy-back - Appendix 3C
17/10/12	PRICE SENSITIVE	89.61KB	Share
CSLFull Year Results, Appendix 4E and Analysts Presentation
22/08/12	PRICE SENSITIVE	3.9MB	Share
CSLCEO Succession
03/08/12	PRICE SENSITIVE	36.47KB	Share
CSLChanges relating to buy-back - Appendix 3D
19/03/12	PRICE SENSITIVE	66.27KB	Share
CSLHalf Year Report and Accounts
22/02/12	PRICE SENSITIVE	950.46KB	Share
CSLChanges relating to buy-back - Appendix 3D
09/11/11	PRICE SENSITIVE	85.5KB	Share
CSLAnnouncement of buy-back
19/10/11	PRICE SENSITIVE	21.63KB	Share
CSLChairmans and MDs address to shareholders
19/10/11	PRICE SENSITIVE	268.59KB	Share
CSLFull Year Results, Appendix 4E and Analysts Presentation
17/08/11	PRICE SENSITIVE	1.08MB	Share
CSLRecombinant Technologies
20/05/11	PRICE SENSITIVE	64.4KB	Share
CSLHalf Yearly Report and Accounts
16/02/11	PRICE SENSITIVE	913.55KB	Share
CSLChairman's Address to Shareholders
13/10/10	PRICE SENSITIVE	268.63KB	Share
CSLAnnouncement of buy-back - Appendix 3C
18/08/10	PRICE SENSITIVE	70.86KB	Share
CSLFull Year Results, Appendix 4E and Analysts Presentation
18/08/10	PRICE SENSITIVE	1.74MB	Share
CSL +PABPatrys Reaches First Milestone in CSL Collaboration
28/05/10	PRICE SENSITIVE	192.44KB	Share
CSLResponse to an ASX Query
23/04/10	PRICE SENSITIVE	217.52KB	Share
CSLHalf Yearly Report and Accounts
17/02/10	PRICE SENSITIVE	323.48KB	Share
CSL +PABPatrys - CSL Collaboration
28/01/10	PRICE SENSITIVE	79.32KB	Share
CSLChanges relating to buy-back - Appendix 3D
20/10/09	PRICE SENSITIVE	14.98KB	Share
CSLChairman's and MD's Address to Shareholders
14/10/09	PRICE SENSITIVE	350.44KB	Share
CSLFull Year Results, Appendix 4E and Analysts Presentation
19/08/09	PRICE SENSITIVE	1.8MB	Share
CSLAccounting Treatment - Conversion of US $1.5B to AUD
22/06/09	PRICE SENSITIVE	82.73KB	Share
CSLPhosphagenics signs agreement with CSL
19/06/09	PRICE SENSITIVE	18.63KB	Share
CSLCSL and Talecris agree to terminate Merger Agreement
09/06/09	PRICE SENSITIVE	104.67KB	Share
CSLCSL announces on-market share buyback
09/06/09	PRICE SENSITIVE	82.45KB	Share
CSLAnnouncement of buy-back - Appendix 3C
09/06/09	PRICE SENSITIVE	17.46KB	Share
CSLCSL Receives Order from U.S,. Government for H1N1 Vaccine
29/05/09	PRICE SENSITIVE	35.51KB	Share
CSLConfirms commitment to Talecris acquisition
28/05/09	PRICE SENSITIVE	89.17KB	Share
CSLProposed Acquisition of Talecris
07/05/09	PRICE SENSITIVE	33.74KB	Share
CSLHalf Yearly Report and Accounts
18/02/09	PRICE SENSITIVE	1.13MB	Share

REFRESH

First

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $263.27		Change -0.550(0.21%)		Mkt cap ! $127.4B

Open	High	Low	Value	Volume
$263.30	$265.32	$263.02	$42.05M	159.1K

Buyers (Bids)

No.	Vol.	Price($)
6	50	$263.26

Sellers (Offers)

Price($)	Vol.	No.
$263.28	51	3

View Market Depth

No.	Vol.	Price($)
6	44	263.380
3	271	263.370
1	5	263.340
1	5	263.330
2	10	263.320

Price($)	Vol.	No.
263.410	25	4
263.430	3	1
263.440	28	2
263.450	5	2
263.460	38	3

Last trade - 13.54pm 12/08/2025 (20 minute delay)


Last $264.29		Change -0.550 ( 0.33 %)
Open	High	Low	Volume
$263.85	$265.28	$263.02	34557
Last updated 14.12pm 12/08/2025 ?

CSL (ASX) Chart

CSL LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories